• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4: Cavanaugh Kathryn converted options into 12,825 shares, disposed of 12,825 shares and acquired 12,825 shares

    1/18/22 5:00:38 PM ET
    $CPSR
    Business Services
    Finance
    Get the next $CPSR alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    Cavanaugh Kathryn

    (Last) (First) (Middle)
    GELESIS HOLDINGS, INC.
    501 BOYLSTON STREET, SUITE 6102

    (Street)
    BOSTON, MA 02116

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    GELESIS HOLDINGS, INC. [ GLS ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    01/13/2022
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Class A Common Stock 01/13/2022 M(1) 12,825 A (1) 12,825 D
    Class A Common Stock 01/13/2022 J(2) 12,825 D (2) 0 D
    Common Stock 01/13/2022 J(2) 12,825 A (2) 12,825 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Class B Common Stock (1) 01/13/2022 J(3) 5,175 (1) (1) Class A Common Stock 5,175 (1) 12,825 D
    Class B Common Stock (1) 01/13/2022 M(1) 12,825 (1) (1) Class A Common Stock 12,825 (1) 0 D
    Explanation of Responses:
    1. Immediately prior to the closing of the transactions (the "Closing" of the "Business Combination") contemplated by that certain Business Combination Agreement dated as of July 19, 2021, as amended, by and among the Issuer (f/k/a Capstar Special Purpose Acquisition Corp.), CPSR Gelesis Merger Sub, Inc. and Gelesis, Inc., each share of the Issuer's Class B Common Stock automatically converted into shares of Class A Common Stock on a one-for-one basis (the "Conversion").
    2. Immediately following the Conversion but prior to Closing, the Class A Common Stock was reclassified as Common Stock.
    3. Represents shares of Class B Common Stock forfeited to the Issuer for no consideration in connection with the Business Combination.
    Remarks:
    Exhibit 24 - Power of Attorney
    /s/ David Abraham, Attorney-in-Fact 01/18/2022
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CPSR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CPSR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CPSR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Cavanaugh Kathryn converted options into 12,825 shares, disposed of 12,825 shares and acquired 12,825 shares

      4 - GELESIS HOLDINGS, INC. (0001805087) (Issuer)

      1/18/22 5:00:38 PM ET
      $CPSR
      Business Services
      Finance

    $CPSR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PureTech Health plc – Half-Year Report

      Strong capital base with PureTech Level Cash and Cash Equivalents of $341.4 million1 and Consolidated Cash and Cash Equivalents of $365.9 million2 as of June 30, 2022, excluding up to $115.4 million added post-period3; Operational runway extended into Q1 2026 Significant advancement of PureTech's Wholly Owned Programs, with three clinical trials underway, four completed, and human proof-of-principle achieved for a key PureTech platform Excellent progress across the Founded Entities, including Karuna's positive topline Phase 3 results for KarXT in schizophrenia, Akili's Nasdaq listing and Gelesis' commercial progress with Plenity®4 in the post-period, and four clinical data publications ac

      8/25/22 2:07:00 AM ET
      $CPSR
      $DNAA
      $GLS
      $KRTX
      Business Services
      Finance
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • PureTech Founded Entity Gelesis Announces Clinical Data Demonstrating Weight Loss with GS200 in Adults with Prediabetes and Type 2 Diabetes Presented at the European Congress on Obesity 2022

      Gelesis' six-month study of weight loss in adults with overweight or obesity who have prediabetes or type 2 diabetes met both of its primary endpoints: the proportion of participants who achieved at least 5% body weight loss (i.e., "Categorical") and the change in body weight after six months of therapy GS200 demonstrated a highly favorable Categorial weight loss response and tolerability in a population that often struggles to lose weight and is at high risk for obesity-related complications; the overall incidence of adverse events (AEs) in adults treated with GS200 was similar to the placebo group ~6 out of 10 GS200-treated adults achieved at least 5% weight loss ("Responders"), losing

      5/4/22 6:35:00 AM ET
      $CPSR
      $GLS
      $PRTC
      Business Services
      Finance
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • PureTech Founded Entity Gelesis Announces its Proprietary Superabsorbent Hydrogel Induced Beneficial Changes to the Gut Microbiota and Expanded Akkermansia, a Bacterial Species Associated with Gut Health and Weight Loss, in New Study

      New preclinical data presented today at the World of Microbiome Conference suggest adding superabsorbent hydrogel to a high-fat "western-like" diet prevents unfavorable changes in the communities of gut bacteria associated with diet-induced weight gain PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company announced that its Founded Entity, Gelesis Holdings, Inc. (NYSE:GLS) ("Gelesis), released today a poster prPesentation at the World of Microbiome annual meeting in Vienna. The preclinical study showed administration of one of Gelesis' proprietary superabsorbent hydrogels, Gel-B, significantly shifted the composition of the m

      4/29/22 6:05:00 AM ET
      $CPSR
      $GLS
      $PRTC
      Business Services
      Finance
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CPSR
    SEC Filings

    See more
    • SEC Form 25-NSE filed by Capstar Special Purpose Acquisition Corp.

      25-NSE - GELESIS HOLDINGS, INC. (0001805087) (Subject)

      1/14/22 9:04:44 AM ET
      $CPSR
      Business Services
      Finance
    • Capstar Special Purpose Acquisition Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - CAPSTAR SPECIAL PURPOSE ACQUISITION CORP. (0001805087) (Filer)

      1/12/22 4:09:39 PM ET
      $CPSR
      Business Services
      Finance
    • SEC Form 425 filed by Capstar Special Purpose Acquisition Corp.

      425 - CAPSTAR SPECIAL PURPOSE ACQUISITION CORP. (0001805087) (Subject)

      1/10/22 6:26:59 AM ET
      $CPSR
      Business Services
      Finance

    $CPSR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Capstar Special Purpose Acquisition Corp.

      SC 13G - CAPSTAR SPECIAL PURPOSE ACQUISITION CORP. (0001805087) (Subject)

      9/20/21 4:14:46 PM ET
      $CPSR
      Business Services
      Finance